Liquidia (LQDA) Stock
Clinical stage biopharmaceutical company developing targeted inhaled medicines. Here's the price, business snapshot, and what's worth knowing about Liquidia in October 2026.
Liquidia Corporation (LQDA) is a clinical-stage biopharmaceutical company focused on designing and developing inhaled and targeted medicines using its proprietary PRINT particle-engineering platform. The company aims to improve delivery, dosing consistency and tolerability for respiratory and other conditions through dry-powder and precision-formulated therapies. Investors should be aware that value is heavily tied to clinical trial outcomes, regulatory decisions and potential commercial adoption; revenues may be limited until approval and launch. With a market capitalisation near $2.03 billion, Liquidia can offer upside if its pipeline advances, but also carries significant development, regulatory and commercial risks. Key factors to watch include clinical readouts, partnership agreements, manufacturing scale-up and intellectual-property protection. This summary is for educational purposes and not personalised investment advice — past performance is not a reliable indicator of future results and capital is at risk.
Liquidia (LQDA) Stock Forecast
Analyst price target, next 12 months
$38.53
-9.7% vs today's $42.65
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Liquidia have a consensus 12-month target of $38.53, below the current price of $42.65.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Liquidia Corporation's stock with a target price of $38.53, indicating potential growth.
Financial Health
Liquidia Corporation is performing well with strong revenue and cash flow, indicating good financial strength.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts and regulatory milestones can materially affect valuation, though outcomes are uncertain and may cause share volatility.
Delivery technology edge
The proprietary PRINT particle-engineering platform aims to improve inhaled drug delivery and consistency; technology progress and IP protection matter.
Commercial and partners
Partnerships and manufacturing scale-up influence commercial prospects, but market uptake, pricing and competition remain material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
